The PV market is expanding through increased diagnostic rates and therapeutic innovation. Leading companies like PharmaEssentia, Incyte, and Protagonist Therapeutics are developing novel JAK inhibitors and targeted treatments that improve hematocrit control and reduce symptom burden. Advancements in molecular testing and treatment guidelines are enhancing personalized care approaches for this chronic myeloproliferative neoplasm.
View Market Insights:
https://www.delveinsight.com/i....nfographics/polycyth
Comment
Share
